Maria Ida Abbate1, Diego Luigi Cortinovis2, Marcello Tiseo3, Tiziana Vavalà3,4, Giulio Cerea5, Luca Toschi6, Stefania Canova1, Francesca Colonese1, Paolo Bidoli1. 1. Ospedale San Gerardo, Via GB Pergolesi 33, 20052 Monza, Italy. 2. Azienda Ospedaliera Universitaria, Strada Abbeveratoia 2, Parma, Italy. 3. Azienda Ospedaliero-Sanitaria San Luigi Gonzaga, Regione Gonzole 10, Orbassano, TO, Italy. 4. Presidio Ospedaliero Saluzzo-Savigliano, Via Ospedali, 14, Savigliano, CN, Italy. 5. Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore 3, Milano, Italy. 6. Istituto Clinico Humanitas, Via Alessandro Manzoni 56, Milano, Italy.
Abstract
AIM: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement. PATIENTS & METHODS: NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC). RESULTS: In total, 60 NSCLC patients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months. Smokers had a shorter mOS1 and mOS2 compared with never-smokers; EGFR-mutated patients on tyrosine kinase inhibitors had longer mOS1 and mOS2 than EGFR wild-type patients. CONCLUSION: Metachronous PC is correlated to a short survival, irrespective of treatment line. Never-smokers and EGFR-mutated patients had improved mOS1 and mOS2 when compared with smokers and EGFR wild-type population.
AIM: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement. PATIENTS & METHODS:NSCLCpatients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC). RESULTS: In total, 60 NSCLCpatients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months. Smokers had a shorter mOS1 and mOS2 compared with never-smokers; EGFR-mutated patients on tyrosine kinase inhibitors had longer mOS1 and mOS2 than EGFR wild-type patients. CONCLUSION: Metachronous PC is correlated to a short survival, irrespective of treatment line. Never-smokers and EGFR-mutated patients had improved mOS1 and mOS2 when compared with smokers and EGFR wild-type population.
Authors: Simone Sibio; Giuseppe Sigismondo Sica; Sara Di Carlo; Maurizio Cardi; Alessandra Di Giorgio; Bianca Maria Sollazzo; Paolo Sammartino Journal: J Med Case Rep Date: 2019-08-21